Sudarshan Pharma Industries Ltd
Incorporated in 2008, Sudarshan Pharma Industries Ltd manufactures API and Pharmaceutical Items. It also trades in Chemicals and Solvents[1]
- Market Cap ₹ 1,058 Cr.
- Current Price ₹ 44.0
- High / Low ₹ 45.3 / 5.82
- Stock P/E 79.0
- Book Value ₹ 4.89
- Dividend Yield 0.00 %
- ROCE 13.8 %
- ROE 10.8 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 8.99 times its book value
- Company has a low return on equity of 12.1% over last 3 years.
- Debtor days have increased from 78.7 to 96.5 days.
- Working capital days have increased from 87.0 days to 137 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|
| 148 | 193 | 357 | 461 | 464 | 460 | |
| 143 | 186 | 346 | 446 | 441 | 429 | |
| Operating Profit | 5 | 7 | 11 | 15 | 23 | 31 |
| OPM % | 3% | 4% | 3% | 3% | 5% | 7% |
| 0 | 0 | 0 | 1 | 3 | 1 | |
| Interest | 3 | 3 | 3 | 5 | 9 | 13 |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 2 |
| Profit before tax | 2 | 4 | 7 | 9 | 15 | 17 |
| Tax % | 26% | 25% | 26% | 26% | 25% | |
| 1 | 3 | 5 | 7 | 11 | 13 | |
| EPS in Rs | 0.13 | 0.28 | 0.54 | 0.29 | 0.48 | 0.52 |
| Dividend Payout % | -0% | -0% | -0% | 10% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 34% |
| TTM: | -8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 63% |
| TTM: | 60% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 447% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 12% |
| Last Year: | 11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 24 | 24 | 24 |
| Reserves | 10 | 13 | 20 | 77 | 88 | 94 |
| 21 | 30 | 31 | 34 | 105 | 124 | |
| 18 | 47 | 77 | 97 | 67 | 78 | |
| Total Liabilities | 58 | 99 | 138 | 232 | 283 | 320 |
| 6 | 6 | 6 | 20 | 26 | 25 | |
| CWIP | -0 | -0 | 1 | 0 | 2 | 2 |
| Investments | 0 | -0 | -0 | 12 | 14 | 30 |
| 53 | 93 | 131 | 200 | 242 | 263 | |
| Total Assets | 58 | 99 | 138 | 232 | 283 | 320 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| 1 | 3 | -4 | -29 | 6 | |
| -3 | -1 | -1 | -26 | -5 | |
| -0 | -1 | 4 | 66 | -12 | |
| Net Cash Flow | -2 | -0 | -1 | 11 | -12 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Debtor Days | 66 | 114 | 75 | 64 | 96 |
| Inventory Days | 46 | 49 | 51 | 63 | 74 |
| Days Payable | 40 | 91 | 80 | 78 | 49 |
| Cash Conversion Cycle | 72 | 72 | 46 | 50 | 122 |
| Working Capital Days | 69 | 69 | 54 | 71 | 137 |
| ROCE % | 15% | 19% | 15% | 14% |
Documents
Announcements
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 2d
- Shareholder Meeting / Postal Ballot-Outcome of EGM 2d
-
Addendum To The Notice Of The Extraordinary General Meeting Of Sudarshan Pharma Industries Limited Held On Monday, 30Th September, 2024
18 Nov - Addendum to EGM notice for preferential issue of warrants.
-
Revised Record Date I.E. November 23, 2024 For The Purpose Of Sub-Division/ Split Of Shares Of The Company
8 Nov - Revised record date for equity share sub-division.
- Fixation Of November 18, 2024 As Record Date For The Purpose Of Sub-Division/Split Of Face Value Of Equity Shares Of The Company. 7 Nov
Business Overview:[1][2]
SPIL does jobwork manufacturing in pharmaceutical Items and trading in chemicals and solvents in India. It
specializes in a host of products from rock chemicals intermediates and API to finish formulations and fully
integrated pharmaceutical and chemicals